Cargando…

Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease

Background: Adropin, a peptide translated from the Energy Homeostasis Associated gene (ENHO), was mainly expressed in the liver and was a regulator in metabolic and energy homeostasis. This study aims to investigate the correlation between adropin and histological characteristics of the liver, and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Na, Xie, Guomin, Zhou, Biao, Qu, Aijuan, Meng, Hua, Liu, Jia, Wang, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339918/
https://www.ncbi.nlm.nih.gov/pubmed/34366886
http://dx.doi.org/10.3389/fphys.2021.696163
_version_ 1783733697393983488
author Li, Na
Xie, Guomin
Zhou, Biao
Qu, Aijuan
Meng, Hua
Liu, Jia
Wang, Guang
author_facet Li, Na
Xie, Guomin
Zhou, Biao
Qu, Aijuan
Meng, Hua
Liu, Jia
Wang, Guang
author_sort Li, Na
collection PubMed
description Background: Adropin, a peptide translated from the Energy Homeostasis Associated gene (ENHO), was mainly expressed in the liver and was a regulator in metabolic and energy homeostasis. This study aims to investigate the correlation between adropin and histological characteristics of the liver, and the clinical relevance of adropin in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods: A total of 62 subjects, including 32 healthy controls and 30 MAFLD patients, were enrolled in this case-control study. The MAFLD patients were further divided into two subgroups, including NGT-M group and T2DM-M group. Serum adropin levels, metabolic parameters and intrahepatic lipids, the liver ENHO mRNA expressions and histological characteristics were investigated. Results: MAFLD patients showed significantly lower circulating adropin compared with healthy controls (2.02 ± 2.92 vs. 5.52 ± 0.65 ng/mL, P < 0.0001). Subgroup analysis exhibited dramatically declined serum adropin levels in T2DM-M patients compared with NGT-M group (0.51 ± 0.73 vs. 4.00 ± 3.52 ng/mL, P < 0.001). H&E and Oil Red O staining show exacerbated steatohepatitis in T2DM-M patients in contrast with NGT-M group. Furthermore, serum adropin concentrations were negatively correlated with intrahepatic triglyceride (TG), total cholesterol (TC), and NAFLD activity score (NAS) (TG: r = −0.495; TC: r = −0.392; NAS: r = −0.451; all P < 0.05). Conclusions: MAFLD patients showed significantly lower adropin levels than the healthy controls, especially in T2DM patients. Adropin maybe a potential biomarker for predicting the development of MAFLD, especially in T2DM individuals.
format Online
Article
Text
id pubmed-8339918
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83399182021-08-06 Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease Li, Na Xie, Guomin Zhou, Biao Qu, Aijuan Meng, Hua Liu, Jia Wang, Guang Front Physiol Physiology Background: Adropin, a peptide translated from the Energy Homeostasis Associated gene (ENHO), was mainly expressed in the liver and was a regulator in metabolic and energy homeostasis. This study aims to investigate the correlation between adropin and histological characteristics of the liver, and the clinical relevance of adropin in patients with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods: A total of 62 subjects, including 32 healthy controls and 30 MAFLD patients, were enrolled in this case-control study. The MAFLD patients were further divided into two subgroups, including NGT-M group and T2DM-M group. Serum adropin levels, metabolic parameters and intrahepatic lipids, the liver ENHO mRNA expressions and histological characteristics were investigated. Results: MAFLD patients showed significantly lower circulating adropin compared with healthy controls (2.02 ± 2.92 vs. 5.52 ± 0.65 ng/mL, P < 0.0001). Subgroup analysis exhibited dramatically declined serum adropin levels in T2DM-M patients compared with NGT-M group (0.51 ± 0.73 vs. 4.00 ± 3.52 ng/mL, P < 0.001). H&E and Oil Red O staining show exacerbated steatohepatitis in T2DM-M patients in contrast with NGT-M group. Furthermore, serum adropin concentrations were negatively correlated with intrahepatic triglyceride (TG), total cholesterol (TC), and NAFLD activity score (NAS) (TG: r = −0.495; TC: r = −0.392; NAS: r = −0.451; all P < 0.05). Conclusions: MAFLD patients showed significantly lower adropin levels than the healthy controls, especially in T2DM patients. Adropin maybe a potential biomarker for predicting the development of MAFLD, especially in T2DM individuals. Frontiers Media S.A. 2021-07-22 /pmc/articles/PMC8339918/ /pubmed/34366886 http://dx.doi.org/10.3389/fphys.2021.696163 Text en Copyright © 2021 Li, Xie, Zhou, Qu, Meng, Liu and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Li, Na
Xie, Guomin
Zhou, Biao
Qu, Aijuan
Meng, Hua
Liu, Jia
Wang, Guang
Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease
title Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease
title_full Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease
title_fullStr Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease
title_full_unstemmed Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease
title_short Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease
title_sort serum adropin as a potential biomarker for predicting the development of type 2 diabetes mellitus in individuals with metabolic dysfunction-associated fatty liver disease
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339918/
https://www.ncbi.nlm.nih.gov/pubmed/34366886
http://dx.doi.org/10.3389/fphys.2021.696163
work_keys_str_mv AT lina serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease
AT xieguomin serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease
AT zhoubiao serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease
AT quaijuan serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease
AT menghua serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease
AT liujia serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease
AT wangguang serumadropinasapotentialbiomarkerforpredictingthedevelopmentoftype2diabetesmellitusinindividualswithmetabolicdysfunctionassociatedfattyliverdisease